| Identification | Back Directory | [Name]
SB 215505 | [CAS]
162100-15-4 | [Synonyms]
6-chloro-5-methyl-N-quinolin-5-yl-2,3-dihydroindole-1-carboxamide
6-Chloro-2,3-dihydro-5-methyl-N-5-quinolinyl-1H-indole-1-carboxamide
1H-Indole-1-carboxamide, 6-chloro-2,3-dihydro-5-methyl-N-5-quinolinyl- | [Molecular Formula]
C19H16ClN3O | [MDL Number]
MFCD05664741 | [MOL File]
162100-15-4.mol | [Molecular Weight]
337.8 |
| Chemical Properties | Back Directory | [Boiling point ]
600.9±55.0 °C(Predicted) | [density ]
1.385±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C
| [solubility ]
DMSO: ~11 mg/mL at 60 °C, soluble
| [form ]
solid
| [pka]
12.87±0.20(Predicted) | [color ]
off-white
| [InChI]
1S/C19H16ClN3O/c1-12-10-13-7-9-23(18(13)11-15(12)20)19(24)22-17-6-8-21-16-5-3-2-4-14(16)17/h2-6,8,10-11H,7,9H2,1H3,(H,21,22,24) | [InChIKey]
BPVGSWDWIRIUME-UHFFFAOYSA-N | [SMILES]
Cc1cc2CCN(C(=O)Nc3ccnc4ccccc34)c2cc1Cl |
| Hazard Information | Back Directory | [Uses]
SB-215505 is a selective 5-HT2B serotonin receptor antagonist. | [Biological Activity]
Selective 5-HT2B serotonin receptor antagonist; 100-fold higher affinity at 2B versus 2C. | [in vivo]
SB-215505 (0.1-1.0 mg/kg; i.p.; two doses) dose-dependently increases wakefulness (W) and decreases IS, PS, SWS-2[2]. | Animal Model: | Male Sprague-Dawley rats weighing 230-260 g[2] | | Dosage: | 0.1, 0.3 and 1.0 mg/kg | | Administration: | IP; two doses (4 days between two doses) | | Result: | Dose-dependently increased wakefulness (W) and decreased intermediate stage of sleep (IS), paradoxical sleep (PS), SWS-2.
|
| [IC 50]
5-HT2B Receptor: 8.3 (pKi); 5-HT2A Receptor: 6.77 (pKi); 5-HT2C Receptor: 7.66 (pKi) |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|